Search results for "RATES"

showing 10 items of 1636 documents

Comparison of high-pressure liquid chromatography (HPLC) and Griess reagent-spectroscopic methods for the measurement of nitrate in serum from health…

2008

Bioavailability of NO can be estimated by measuring the concentration of nitrate (NO(3)) in serum. However, the methods used for the measurement NO(3) in plasma or serum show a great degree of variation. Therefore, we compared two analytical methods for the measurement of NO(3) in serum.The concentration of NO(3) in 600 serum samples collected from healthy individuals was determined by the HPLC and by the Griess reagent-spectroscopic method.The concentration of NO(3) in the samples was 29.4+/-16.1 micromol/L and 26.2+/-14.0 micromol/L (mean+/-SD) measured by HPLC and Griess reagent-spectroscopic method respectively (p0.0001). We detected a significant correlation between the two methods (R=…

Adultinorganic chemicalsAdolescentClinical BiochemistryHigh-performance liquid chromatographyYoung Adultchemistry.chemical_compoundNitrateGriess testSulfanilamidesHumansHplc methodReference standardsChromatography High Pressure LiquidAgedAged 80 and overNitratesChromatographySpectrum Analysisorganic chemicalsfood and beveragesGeneral MedicineMiddle AgedReference StandardsEthylenediaminesSerum samplesBioavailabilitychemistryHealthy individualsClinical Biochemistry
researchProduct

Evaluation of carpal tunnel syndrome in patients with polyneuropathy

1997

The difference between the median nerve latency to the second lumbrical muscle and the ulnar nerve latency to the second interosseous muscle (L-I DIFF) was tested in a prospective study to discriminate whether prolonged distal motor latency of the median nerve in patients with polyneuropathy (PNP) reflects an additional carpal tunnel syndrome (CTS). We investigated 92 patients (107 hands) with CTS, 30 patients (34 hands) with PNP, 22 patients (27 hands) with CTS and coexisting PNP (PNP+CTS), and 77 controls (87 hands). L-I DIFF was significantly prolonged in both the CTS and PNP+CTS patients as compared to PNP patients and controls. It proved to be the most specific test to differentiate be…

Adultinorganic chemicalsmedicine.medical_specialtyPhysiologyNeural ConductionNerve conduction velocityCellular and Molecular NeurosciencePhysiology (medical)medicineHumansheterocyclic compoundsIn patientNeurons AfferentProspective cohort studyUlnar nerveCarpal tunnel syndromeUlnar NerveAgedMotor Neuronsmedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseCarpal Tunnel SyndromeMedian nerveMedian Nervenervous system diseasesSurgeryenzymes and coenzymes (carbohydrates)Evaluation Studies as TopicNerve conduction studyNeurology (clinical)businessPolyneuropathyDemyelinating DiseasesMuscle & Nerve
researchProduct

Effects of leflunomide (HWA 486) on expression of lymphocyte activation markers

1993

Leflunomide (HWA 486), an isoxazol derivative, has been shown to be very effective in combating autoimmune diseases and transplantation rejection in a great number of animal models. The main metabolite of leflunomide, A77 1726, is a potent antiproliferative compound. To further elucidate this effect, lymphocytes of healthy human donors were cultured for 24, 48 or 72 h in the presence of PHA or immobilized anti-CD3 antibody. A77 1726 was added at concentrations between 10 and 100 microM. Flow cytometric evaluation of early activation or proliferation markers (IL-2 and transferrin receptors, respectively) showed that their expression was inhibited in a dose-dependent manner by A77 1726. Toget…

Adultmedicine.medical_specialtyAllergyToluidinesMetaboliteImmunologyHydroxybutyratesTransferrin receptorBiologyPharmacologyLymphocyte ActivationToxicologychemistry.chemical_compoundImmune systemInternal medicineNitrilesReceptors TransferrinmedicineHumansPharmacology (medical)PhytohemagglutininsLeflunomidePharmacologyAniline CompoundsAnti-Inflammatory Agents Non-SteroidalReceptors Interleukin-2Isoxazolesmedicine.diseaseRheumatologyTransplantationchemistryCrotonatesImmunologybiology.proteinAntibodyBiomarkersLeflunomidemedicine.drugAgents and Actions
researchProduct

Effects of hypocaloric very-low-carbohydrate diet vs. Mediterranean diet on endothelial function in obese women

2009

Obesity is a cardiovascular risk factor associated with endothelial dysfunction, but the effect of different weight loss strategies on endothelial function is not known. The effect of diet on endothelial function in two hypocaloric diets, a very-low-carbohydrate diet (A) and a Mediterranean diet (M), was measured by brachial artery flow-mediated dilation (FMD). Design Using a longitudinal, randomized, open study design, subjects were engaged in a 2-month weight loss diet. FMD, inflammatory cytokines [interleukin-6 (IL-6) and tumour necrosis factor-alpha] and a marker of oxidative stress [8-iso-prostaglandin F2alpha (8-iso-PGF2alpha)] were measured in subjects on three occasions: before init…

Adultmedicine.medical_specialtyBrachial ArteryEndotheliumMediterranean dietClinical BiochemistryOverweightDiet MediterraneanBiochemistryBody Mass IndexDieta ipoglicidica dieta meditarrenea funzione endotelialeDiet Carbohydrate-RestrictedRisk FactorsWeight lossInternal medicineDietary CarbohydratesmedicineHumansLongitudinal StudiesObesityEndothelial dysfunctionbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseDietary FatsObesityEndocrinologymedicine.anatomical_structureRegional Blood FlowFemaleEndothelium Vascularmedicine.symptombusinessBody mass indexDietingEuropean Journal of Clinical Investigation
researchProduct

Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience

2019

Teriflunomide (TRF) and Dimethyl fumarate (DMF) are licensed drugs for relapsing-remitting Multiple Sclerosis (RRMS). We aimed to compare the rate and the time to discontinuation among persons with RRMS (pwRRMS), newly treated with TRF and DMF. A retrospective study on prospectively collected data was performed in nine tertiary MS centers, in Italy. The 24-month discontinuation rate in the two cohorts was the primary study outcome. We also assessed the time to discontinuation and reasons of therapy withdrawn. Discontinuation of TRF and DMF was defined as a gap of treatment ≥ 60 days. A cohort of 903 pwRRMS (316 on TRF and 587 on DMF) was analyzed. During 24 months of follow-up, pwRRMS on TR…

Adultmedicine.medical_specialtyDiscontinuation rateTime FactorsToluidinesPopulationHydroxybutyratesRelapsing-RemittingDimethyl fumarateMultiple sclerosis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicineTeriflunomideNitrilesTeriflunomidemedicineHumansMultiple sclerosi030212 general & internal medicineeducationRetrospective Studieseducation.field_of_studyDimethyl fumaratebusiness.industryProportional hazards modelMultiple sclerosisDimethyl fumarate; Discontinuation rate; Multiple sclerosis; Real-life; Teriflunomide; Neurology; Neurology (clinical)Real-lifeRetrospective cohort studyMiddle Agedmedicine.diseaseDiscontinuationchemistryItalyNeurologyCrotonatesCohortDimethyl fumarate; Discontinuation rate; Multiple sclerosis; Real-life; Teriflunomide; Adult; Crotonates; Dimethyl Fumarate; Follow-Up Studies; Humans; Immunosuppressive Agents; Italy; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Retrospective Studies; Time Factors; ToluidinesNeurology (clinical)business030217 neurology & neurosurgeryImmunosuppressive AgentsFollow-Up Studies
researchProduct

C4-dicarboxylate carriers and sensors in bacteria

2002

AbstractBacteria contain secondary carriers for the uptake, exchange or efflux of C4-dicarboxylates. In aerobic bacteria, dicarboxylate transport (Dct)A carriers catalyze uptake of C4-dicarboxylates in a H+- or Na+-C4-dicarboxylate symport. Carriers of the dicarboxylate uptake (Dcu)AB family are used for electroneutral fumarate:succinate antiport which is required in anaerobic fumarate respiration. The DcuC carriers apparently function in succinate efflux during fermentation. The tripartite ATP-independent periplasmic (TRAP) transporter carriers are secondary uptake carriers requiring a periplasmic solute binding protein. For heterologous exchange of C4-dicarboxylates with other carboxylic …

Aerobic bacteriaAntiporterSuccinic AcidBiophysicsOrganic Anion TransportersReceptors Cell Surfacemedicine.disease_causeBiochemistryFumarate (succinate) sensorTwo-component systemBacterial ProteinsFumaratesEscherichia colimedicineAmino Acid SequenceEscherichia coliDicarboxylate uptake SHistidine protein kinasePhylogenyHistidineDicarboxylic Acid TransportersDicarboxylate transport BbiologyEscherichia coli ProteinsBiological TransportPeriplasmic spaceCell Biologybiology.organism_classificationTwo-component regulatory systemBacteria AerobicModels ChemicalBiochemistryAntiportFumarate/succinate transportEffluxDicarboxylate uptake carrierProtein KinasesDicarboxylate transport A carrierBacteriaSignal TransductionBiochimica et Biophysica Acta (BBA) - Bioenergetics
researchProduct

Purification and characterisation of a plasmin-sensitive surface protein of Staphylococcus aureus.

1996

Certain methicillin-resistant Staphylococcus aureus strains contain a 230-kDa cell-wall protein which is not present on the surface of other staphylococci. The presence of this 230-kDa protein is associated with a negative test result in commercial assays designed to detect fibrinogen-binding proteins and/or protein A on the staphylococcal surface. We have purified and partially characterised the 230-kDa protein from a lysostaphin digest of a non-agglutinating methicillin-resistant S. aureus strain. Partial amino acid sequence data obtained from the purified protein did not reveal any significant similarities to known proteins which indicates that the protein is novel. The 230-kDa protein w…

AgglutinationStaphylococcus aureusPlasminMolecular Sequence DataCarbohydratesEnzyme-Linked Immunosorbent AssayBiochemistry03 medical and health sciencesAffinity chromatographyBacterial ProteinsCell WallLectinsProtein purificationProtein A/GmedicineTrypsinAmino Acid SequenceFibrinolysinChromatography High Pressure Liquid030304 developmental biology0303 health sciencesMembrane GlycoproteinsbiologySequence Homology Amino Acid030306 microbiologyLysostaphinBinding proteinMolecular biologyPeptide FragmentsMolecular WeightBiochemistrybiology.proteinElectrophoresis Polyacrylamide GelMethicillin ResistanceProtein GProtein Amedicine.drugEuropean journal of biochemistry
researchProduct

ADAM-10 over-expression increases cortical synaptogenesis.

2006

Cortical cholinergic, glutamatergic and GABAergic terminals become upregulated during early stages of the transgenic amyloid pathology. Abundant evidence suggests that sAPP alpha, the product of the non-amyloidogenic alpha-secretase pathway, is neurotrophic both in vitro and when exogenously applied in vivo. The disintegrin metalloprotease ADAM-10 has been shown to have alpha-secretase activity in vivo. To determine whether sAPP alpha has an endogenous biological influence on cortical presynaptic boutons in vivo, we quantified cortical cholinergic, glutamatergic and GABAergic presynaptic bouton densities in either ADAM-10 moderate expressing (ADAM-10 mo) transgenic mice, which moderately ov…

Agingmedicine.medical_specialtySynaptogenesisPresynaptic TerminalsAlpha (ethology)Mice TransgenicBiologyReceptors Metabotropic GlutamateGlutamatergicADAM10 ProteinMiceReceptors GABAInternal medicinemedicineAnimalsHumansReceptors CholinergicCerebral CortexGeneral NeuroscienceGene Expression Regulation DevelopmentalMembrane Proteinscarbohydrates (lipids)ADAM Proteinsmedicine.anatomical_structureEndocrinologyCerebral cortexSynaptic plasticitySynapsesbiology.proteinGABAergicCholinergicCattleNeurology (clinical)Geriatrics and GerontologyAmyloid Precursor Protein SecretasesDevelopmental BiologyNeurotrophinNeurobiology of aging
researchProduct

Adrenergic activation of phospholipase D in primary rat astrocytes.

1996

Phospholipase D (PLD) activity was investigated in astrocytes prepared from newborn rat cerebral cortex using the transphosphatidylation assay. Basal PLD activity was measurable and was found to be enhanced by ATP, carbachol and noradrenaline. The activation by noradrenaline (EC50, 0.68 microM) was mimicked by methoxamine (EC50, 65 microM), an alpha 1-specific adrenergic agonist, and was inhibited by prazosine, an alpha 1-specific adrenergic antagonist. Clonidin, an alpha 2-adrenergic agonist, slightly lowered PLD activity whereas beta-adrenergic drugs were without effect. Experiments with mitogens indicate that PLD activation in astrocytes may be involved in the control of astrocytic cell …

Agonistmedicine.medical_specialtyCarbacholmedicine.drug_classAdrenergicBiologyMethoxamineMethoxamineNorepinephrineInternal medicinemedicineAdrenergic antagonistPhospholipase DAnimalsAdrenergic agonistCells CulturedDose-Response Relationship DrugPhospholipase DGeneral NeuroscienceRatsenzymes and coenzymes (carbohydrates)Endocrinologymedicine.anatomical_structureAstrocytesNeuroglialipids (amino acids peptides and proteins)medicine.drugNeuroscience letters
researchProduct

Manejo de la hiperglucemia con fármacos no insulínicos en pacientes adultos con diabetes tipo 2

2019

Resumen: El adecuado tratamiento de la diabetes mellitus tipo 2 (DM2) incluye la alimentación saludable y el ejercicio (150 min/semana) como pilares básicos. Para el tratamiento farmacológico, la metformina es el fármaco de elección inicial, salvo contraindicación o intolerancia; en caso de mal control, se dispone de 8 familias terapéuticas (6 orales y 2 inyectables) como posibles combinaciones. Se presenta un algoritmo y unas recomendaciones para el tratamiento de la DM2. En prevención secundaria cardiovascular se recomienda asociar un inhibidor del cotransportador sodio-glucosa tipo 2 (iSGLT2) o un agonista del receptor de glucagon-like peptide-1 (arGLP1) en pacientes con obesidad. En pre…

Agonistmedicine.medical_specialtymedicine.drug_class030204 cardiovascular system & hematologyOverweight:Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet::Diabetic Diet [Medical Subject Headings]GastroenterologyDiabetes tipo 2:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]03 medical and health sciences0302 clinical medicineFármacos antidiabéticos:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperglycemia [Medical Subject Headings]Internal medicineDiabetes mellitusmedicineGliclazide030212 general & internal medicineHiperglucemiaContraindicationlcsh:R5-920business.industryAntidiabetic drugs:Diseases::Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus Type 2 [Medical Subject Headings]nutritional and metabolic diseases:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Psychology Social::Life Style [Medical Subject Headings]Type 2 diabetesGeneral Medicinemedicine.diseaseSulfonylureaObesityHumanos:Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity [Medical Subject Headings]MetforminHyperglycemia:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hypoglycemic Agents [Medical Subject Headings]medicine.symptomlcsh:Medicine (General)Family Practicebusinessmedicine.drug
researchProduct